Successful treatment of SAPHO syndrome with zoledronic acid

Arthritis and Rheumatism

Volumn 50, Issue 9, 2004, Pages 2970-2973

  Kopterides, Petros ^a,b   Pikazis, Dimitrios ^a   Koufos, Christos ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; STEROID; TECHNETIUM 99M; ZOLEDRONIC ACID;

ACNE; ADULT; ARTICLE; BONE SCINTISCANNING; CASE REPORT; CLINICAL FEATURE; DISEASE CONTROL; HUMAN; HYPEROSTOSIS; MALE; OSTEITIS; PRIORITY JOURNAL; PUSTULOSIS; RELAPSE; SAPHO SYNDROME; SIDE EFFECT; STEROID THERAPY; SYNOVITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ACQUIRED HYPEROSTOSIS SYNDROME; ADOLESCENT; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; TREATMENT OUTCOME;

EID: 4444308502     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20464     Document Type: Article

References (12)

1. Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey: 85 cases. Rev Rheum Mal Osteoartic 1987;54:187-96.
2. Marshall H, Bromilow J, Thomas AL, Arden NK. Pamidronate: a novel treatment for the SAPHO syndrome? Rheumatology (Oxford) 2002;41:231-3.
3. Guignard S, Job-Deslandre C, Sayag-Boukris V, Kahan A. Pamidronate treatment in SAPHO syndrome. Joint Bone Spine 2002;69:392-6.
4. Soubrier M, Dubost JJ, Ristori JM, Sauvezie B, Bussiere JL. Pamidronate in the treatment of diffuse sclerosing osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:637-40.
5. Courtney PA, Hosking DJ, Fairbairn KJ, Deighton CM. Treatment of SAPHO with pamidronate. Rheumatology (Oxford) 2002;41:1196-8.
6. Giedion A, Holthusen W, Masel LF, Vischer D. Subacute and chronic "symmetrical" osteomyelitis. Ann Radiol (Paris) 1972;15: 329-42.
7. Suei Y, Taguchi A, Tanimoto K. Diffuse sclerosing osteomyelitis of the mandible: its characteristics and possible relationship to synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. J Oral Maxillofac Surg 1996;54:1194-9.
8. Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E, Silbermann-Hoffmann O, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 1999;29:159-71.
9. Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNF α secretion from RAW 264 cells in vitro. Pharm Res 1995;12:916-22.
10. Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 2001;28(2 Suppl 6):4-10.
11. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-63.
12. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-9.